Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli

Medicamentos para prevenir las cefaleas migrañosas en los niños
Characteristics of included studies
Study
Methods
Participants
Interventions
Outcomes
Notes
Allocation concealment
Study
Methods
Participants
Interventions
Outcomes
Notes
Allocation concealment
Study
Methods
Longo 1984
Randomised, double-blind, placebo-controlled, crossover.
Randomisation not described. Method of blinding not described.
Headaches 'typical' of migraine.
Symptomatic treatment and compliance not reported.
30 randomised. 10 withdrawals.
Group A (15 patients) and Group B (15 patients) were roughly comparable.
18/30 males. Mean age 10.38 +/- 1.86 years.
A: L-5HTP 100 mg daily for 6 weeks, then 6 weeks placebo daily.
B: 6 weeks of placebo daily, then 6 weeks of L-5HTP 100 mg daily.
Migraine index.
Only graphical representation of data. Investigators reported statistically significant
reduction of outcome when using L-5HTP.
10 withdrawals. 3 - did not complete diary; 3 - ineffective treatment; 1 - adverse events;
3 - resolution of symptoms.
No adverse events reported.
Migraine index not defined.
B
Ludvigsson 1974
Randomised, double-blind, placebo-controlled, crossover.
Randomisation not described. Method of blinding not described.
Migraine by Ad Hoc Committee 1962.
Symptomatic treatment permitted (no rules described). Compliance measured using
pill count (3 non-compliers).
32 randomised. 4 withdrawals.
Group comparability not known.
18/32 males. Age range: 7 to 16 years.
A: Propranolol (built up during the first week to a maximum of 60 mg/day in 3 doses
for children weighing less than 35 kg and 120 mg/day in 3 doses for children weighing
35 kg or more) for 13 weeks, followed by placebo for 13 weeks.
B: Placebo for 13 weeks followed by propranolol (as above) for 13 weeks.
Frequency.
Statistically significant reduction in frequency with propranolol. Two non-responders.
4 dropouts. 3 failed to take medications regularly. 1 withdrawn for surgery.
Adverse events: 2 - difficulty in falling asleep.
B
Lutschg 1990
Randomised, double-blind, drug-drug comparison, parallel-group.
Randomisation not described. Method of blinding not described.
Migraine defined as episodic headaches impairing performance, plus at least 3 of the
following: pulsating, frequently unilateral, vomiting, nausea, photophobia, visual
impairment, and positive family history.
Symptomatic treatment permitted (aspegic or alcalyl). Compliance not reported.
Página 23
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.